CR20210222A - METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN - Google Patents
METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZINInfo
- Publication number
- CR20210222A CR20210222A CR20210222A CR20210222A CR20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A CR 20210222 A CR20210222 A CR 20210222A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dapagliflozin
- methods
- kidney disease
- chronic kidney
- treatment
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 2
- 229960003834 dapagliflozin Drugs 0.000 title abstract 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente divulgación se refiere a métodos de tratamiento de pacientes con enfermedad renal crónica (ERC), con y sin diabetes tipo 2, con un inhibidor de SGLT2, tal como dapagliflozina.The present disclosure relates to methods of treating chronic kidney disease (CKD) patients, with and without type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057139P | 2020-07-27 | 2020-07-27 | |
| US202063070869P | 2020-08-27 | 2020-08-27 | |
| US202063082524P | 2020-09-24 | 2020-09-24 | |
| US202063093961P | 2020-10-20 | 2020-10-20 | |
| US202063119711P | 2020-12-01 | 2020-12-01 | |
| US202163152445P | 2021-02-23 | 2021-02-23 | |
| US202163161629P | 2021-03-16 | 2021-03-16 | |
| PCT/EP2021/058727 WO2022022865A1 (en) | 2020-07-27 | 2021-04-01 | Methods of treating chronic kidney disease with dapagliflozin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210222A true CR20210222A (en) | 2022-08-29 |
Family
ID=79551924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210222A CR20210222A (en) | 2020-07-27 | 2021-04-01 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4188389A1 (en) |
| JP (1) | JP2023536009A (en) |
| KR (2) | KR20230149329A (en) |
| CN (3) | CN116392472A (en) |
| AU (2) | AU2021202643B2 (en) |
| BR (1) | BR112021008094A2 (en) |
| CA (1) | CA3116533A1 (en) |
| CR (1) | CR20210222A (en) |
| DO (1) | DOP2021000083A (en) |
| IL (1) | IL282665A (en) |
| JO (1) | JOP20210087A1 (en) |
| MX (1) | MX2021005191A (en) |
| PE (1) | PE20231306A1 (en) |
-
2021
- 2021-04-01 KR KR1020237034971A patent/KR20230149329A/en active Search and Examination
- 2021-04-01 EP EP21716724.6A patent/EP4188389A1/en active Pending
- 2021-04-01 CN CN202310547700.1A patent/CN116392472A/en active Pending
- 2021-04-01 AU AU2021202643A patent/AU2021202643B2/en active Active
- 2021-04-01 BR BR112021008094A patent/BR112021008094A2/en unknown
- 2021-04-01 MX MX2021005191A patent/MX2021005191A/en unknown
- 2021-04-01 CN CN202210071080.4A patent/CN114209689B/en active Active
- 2021-04-01 CN CN202180001003.5A patent/CN114630682A/en active Pending
- 2021-04-01 PE PE2021000657A patent/PE20231306A1/en unknown
- 2021-04-01 JP JP2021523830A patent/JP2023536009A/en active Pending
- 2021-04-01 CA CA3116533A patent/CA3116533A1/en active Pending
- 2021-04-01 JO JOP/2021/0087A patent/JOP20210087A1/en unknown
- 2021-04-01 KR KR1020217013222A patent/KR20220097854A/en not_active IP Right Cessation
- 2021-04-01 CR CR20210222A patent/CR20210222A/en unknown
- 2021-04-26 IL IL282665A patent/IL282665A/en unknown
- 2021-05-03 DO DO2021000083A patent/DOP2021000083A/en unknown
-
2023
- 2023-04-24 AU AU2023202490A patent/AU2023202490A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202643B2 (en) | 2023-02-02 |
| MX2021005191A (en) | 2022-04-18 |
| JOP20210087A1 (en) | 2023-01-30 |
| EP4188389A1 (en) | 2023-06-07 |
| CN114209689B (en) | 2023-02-17 |
| PE20231306A1 (en) | 2023-08-24 |
| BR112021008094A2 (en) | 2022-02-22 |
| JP2023536009A (en) | 2023-08-23 |
| AU2023202490A1 (en) | 2023-05-11 |
| CN116392472A (en) | 2023-07-07 |
| CN114209689A (en) | 2022-03-22 |
| KR20230149329A (en) | 2023-10-26 |
| CN114630682A (en) | 2022-06-14 |
| CA3116533A1 (en) | 2022-01-27 |
| AU2021202643A1 (en) | 2022-02-10 |
| DOP2021000083A (en) | 2022-04-18 |
| KR20220097854A (en) | 2022-07-08 |
| IL282665A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018002046A2 (en) | Lennox-Gastaut Syndrome Treatment Methods Using Fenfluramine | |
| CY1121203T1 (en) | THERAPEUTIC USES OF EMPAGLIFLOSINE | |
| CY1120022T1 (en) | Pediatric Acute Acute Lymphoblastic Leukemia Treatment | |
| AR061230A1 (en) | EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| EA201500997A1 (en) | THERAPEUTIC APPLICATIONS OF EMAGOGLIFLOSINE | |
| EA201000673A1 (en) | METHODS AND COMPOSITIONS FOR MEASURING THE ACTIVATION OF Wnt AND FOR TREATING Wnt-MEDIATED CANCER DISEASES | |
| CL2023001351A1 (en) | Methods of treating heart failure by administering omecamtiv mecarbil. | |
| CR11486A (en) | TREATMENT OF UTERINE CANCER AND OVARIO CANCER WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS | |
| MX2021000295A (en) | Dimeric immuno-modulatory compounds against cereblon-based mechanisms. | |
| MX355482B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy. | |
| EA202192122A1 (en) | COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION | |
| EA201170425A1 (en) | TETRACYCLINE CONNECTIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT | |
| MX2021000847A (en) | Methods of treating cancer with pi3k inhibitor, gdc-0077. | |
| CL2011001943A1 (en) | Antibiotic therapy to treat or prevent post-infectious irritable bowel syndrome. | |
| MX2021013974A (en) | Tl1a patient selection methods, systems, and devices. | |
| UY39156A (en) | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | |
| PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| BR112022003659A2 (en) | Compositions and methods of treatment of vascular diseases | |
| EA202092824A1 (en) | COMBINATION THERAPY | |
| DOP2021000083A (en) | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | |
| AR121738A1 (en) | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | |
| EA202091112A1 (en) | SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION | |
| CO6670518A2 (en) | Treatment of clostridium difficulty in patients under antibiotic therapy | |
| EA202090558A1 (en) | SCHEMES OF TREATMENT |